Previous studies have shown that the gut microbiome and microbe-derived metabolites influence the anti-PD-1/PD-L1 therapy response and can be used to predict therapy outcomes in non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and melanoma [7, 8]. This evidence concerns the gene CD274 and renal cell carcinoma.